MX2022015734A - Proteinas de exotoxina a modificadas. - Google Patents

Proteinas de exotoxina a modificadas.

Info

Publication number
MX2022015734A
MX2022015734A MX2022015734A MX2022015734A MX2022015734A MX 2022015734 A MX2022015734 A MX 2022015734A MX 2022015734 A MX2022015734 A MX 2022015734A MX 2022015734 A MX2022015734 A MX 2022015734A MX 2022015734 A MX2022015734 A MX 2022015734A
Authority
MX
Mexico
Prior art keywords
modified
proteins
antigens
exotoxin
relates
Prior art date
Application number
MX2022015734A
Other languages
English (en)
Inventor
Stefan Jochen Kemmler
Julien Laurent Quebatte
Christian Lizak
Gerald Johann Posch
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2022015734A publication Critical patent/MX2022015734A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99019—Undecaprenyl-diphosphooligosaccharide—protein glycotransferase (2.4.99.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se relaciona con el campo de las proteínas modificadas, composiciones inmunogénicas y vacunas que comprenden las proteínas modificadas, su fabricación y el uso de tales composiciones en la medicina. Más en particular, se relaciona con una proteína EPA modificada (Exotoxina A de Pseudomonas aeruginosa). La EPA modificada puede utilizarse como una proteína portadora de otros antígenos, en particular de antígenos de sacárido u otros antígenos que carecen de los epítopos de células T.
MX2022015734A 2020-06-25 2021-06-17 Proteinas de exotoxina a modificadas. MX2022015734A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063043883P 2020-06-25 2020-06-25
EP20182139 2020-06-25
EP20182138 2020-06-25
PCT/EP2021/066336 WO2021259742A1 (en) 2020-06-25 2021-06-17 Modified exotoxin a proteins

Publications (1)

Publication Number Publication Date
MX2022015734A true MX2022015734A (es) 2023-01-18

Family

ID=76375084

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022015734A MX2022015734A (es) 2020-06-25 2021-06-17 Proteinas de exotoxina a modificadas.
MX2022016589A MX2022016589A (es) 2020-06-25 2021-06-17 O-antigeno de klebsiella pneumoniae.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022016589A MX2022016589A (es) 2020-06-25 2021-06-17 O-antigeno de klebsiella pneumoniae.

Country Status (8)

Country Link
US (2) US20230293657A1 (es)
EP (2) EP4171624A1 (es)
JP (2) JP2023531242A (es)
CN (2) CN116209753A (es)
BR (2) BR112022023234A2 (es)
CA (2) CA3185642A1 (es)
MX (2) MX2022015734A (es)
WO (2) WO2021259743A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022249034A1 (en) * 2021-05-26 2022-12-01 Pfizer Inc. Recombinant expression of klebsiella pneumoniae o-antigens in escherichia coli
WO2023118033A1 (en) * 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
WO2024089001A1 (en) * 2022-10-24 2024-05-02 Idorsia Pharmaceuticals Ltd Vaccine against klebsiella pneumoniae

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
NZ249704A (en) 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
ES2200059T3 (es) 1995-03-22 2004-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Produccion de construcciones inmunogenicas usando carbohidratos solubles activados mediante reactivos cianilados organicos.
CA2477794C (en) 2002-03-07 2013-08-20 Eidgenoessische Technische Hochschule Zuerich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2853600B1 (en) 2005-05-11 2018-09-19 ETH Zürich Recombinant N-glycosylated proteins from procaryotic cells
EP3427749A1 (en) 2008-02-20 2019-01-16 GlaxoSmithKline Biologicals SA Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
WO2011006261A1 (en) 2009-07-17 2011-01-20 Ocean Harvest Technology (Canada) Inc. Natural and sustainable seaweed formula that replaces synthetic additives in fish feed
WO2011062615A1 (en) 2009-11-19 2011-05-26 Glycovaxyn Ag Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
EP2566507B1 (en) * 2010-05-06 2017-11-22 GlaxoSmithKline Biologicals SA Capsular gram-positive bacteria bioconjugate vaccines
US20150238596A1 (en) 2012-09-10 2015-08-27 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
CA2887133C (en) 2012-10-12 2022-05-03 Glycovaxyn Ag Methods of host cell modification
SG11201503308XA (en) 2012-11-07 2015-05-28 Glycovaxyn Ag PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION
EP3055416B1 (en) 2013-10-11 2020-01-22 GlaxoSmithKline Biologicals S.A. Methods of host cell modification
FI3110441T3 (fi) 2014-02-24 2024-05-06 Glaxosmithkline Biologicals S A Uusi polysakkaridi ja sen käyttöjä
EP3177325B1 (en) 2014-08-08 2020-04-01 GlaxoSmithKline Biologicals S.A. Modified host cells and hybrid oligosaccharides for use in bioconjugate production
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
EP3492481A1 (en) * 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae

Also Published As

Publication number Publication date
WO2021259743A2 (en) 2021-12-30
JP2023531242A (ja) 2023-07-21
WO2021259743A3 (en) 2022-04-21
EP4171625A2 (en) 2023-05-03
CA3185639A1 (en) 2021-12-30
CA3185642A1 (en) 2021-12-30
MX2022016589A (es) 2023-02-01
US20230226175A1 (en) 2023-07-20
US20230293657A1 (en) 2023-09-21
BR112022023234A2 (pt) 2023-01-03
WO2021259742A1 (en) 2021-12-30
JP2023531059A (ja) 2023-07-20
CN115996749A (zh) 2023-04-21
BR112022024267A2 (pt) 2023-01-17
EP4171624A1 (en) 2023-05-03
CN116209753A (zh) 2023-06-02

Similar Documents

Publication Publication Date Title
MX2022015734A (es) Proteinas de exotoxina a modificadas.
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
WO2018075857A8 (en) Novel cd47 monoclonal antibodies and uses thereof
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
AU2017297757A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
MX2010003574A (es) Anticuerpos il-23.
EA035991B9 (ru) Новый полисахарид и его применения
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
UA97095C2 (ru) Противораковая вакцина, которая содержит опухолевоассоциированный пептид, который связывается с молекулами лейкоцитарного антигена человека (hla) класса i или ii, и ее применение в производстве лекарственного средства
EA201300322A1 (ru) Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина
NZ711567A (en) Antibody formulations
EA201992570A1 (ru) Составы на основе человеческих антител к rankl, а также способы их применения
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
CR10555A (es) Vacunas para malaria
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
DK2054431T3 (da) Konformere af bakterielle adhæsiner
WO2009042895A3 (en) Reagents for inducing an immune response
MX2020002181A (es) Anticuerpos multiespecificos que se unen especificamente a los epitopos del virus del zika y usos de los mismos.
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
MX2021011137A (es) Formulaciones estabilizadas que contienen anticuerpos anti-il-33.
Tinker et al. Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery
MX2022012545A (es) Peptidos y combinaciones de peptidos para usar en la inmunoterapia contra una infeccion por sars-cov-2 (covid-19).
MX2021007047A (es) Formulaciones de anticuerpos.
ZA202205813B (en) Trpv1 epitopes and antibodies